Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Wyeth drug monitoring test

This article was originally published in The Gray Sheet

Executive Summary

510(k) submission for Abbott's automated test to monitor Rapamune (sirolimus) renal transplant anti-rejection drug response is submitted to FDA under a 2003 collaboration with drug maker Wyeth. Manufacturing partner Axis-Shield is responsible for regulatory clearance. The test will run on Abbott's IMx automated immunoassay analyzer. Abbott already offers tests for cyclosporine and tacrolimus immunosuppressant monitoring. FDA currently is preparing to issue guidance outlining Class II special controls for sirolimus test systems after recently approving Microgenics' Cedia sirolimus assay via the de novo review process (1"The Gray Sheet" Aug. 23, 2004, p. 17)...

Related Content

UsernamePublicRestriction

Register

MT020855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel